(E)-4-(3-nitrophenyl)but-3-en-1-ol | 1426692-71-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (E)-4-(3-nitrophenyl)but-3-en-1-ol
• CAS: 1426692-71-8
• 化学式: C₁₀H₁₁NO₃
• 分子量: 193.202
• InChiKey: VIJWFRSAGJKRKQ-DAFODLJHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  66
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (E)-4-(3-nitrophenyl)but-3-en-1-ol 在 titanium(IV) isopropylate 、 叔丁基过氧化氢 、 3,3'-bis(7-tert-butyl-8-hydroxyquinolin-2-yl)-1,1'-binaphthyl-2,2'-diol 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 16.0h， 以61%的产率得到
  参考文献：
  名称：

  Design of a New Bimetallic Catalyst for Asymmetric Epoxidation and Sulfoxidation

  摘要：

  A new chiral tethered 8-quinolinol-based ligand class is developed. The binuclear titanium complex of the ligand operates through a novel mechanism allowing for the regio- and stereoselective epoxidation of primary and tertiary homoallylic alcohols (up to 98% ee), as well as first examples of 2-allylic phenols (up to 92% ee). The new catalyst system also promotes the asymmetric oxidation of gamma-hydroxypropyl sulfides giving an important class of chiral sulfoxides that have been inaccessible to date (up to 95% ee).

  DOI：

  10.1021/jacs.5b11429
• 作为产物：
  描述：

  间硝基苯甲醛 、 (3-羟丙基)三苯基溴化鏻 在 sodium hexamethyldisilazane 作用下， 以 四氢呋喃 为溶剂， 反应 15.0h， 以80%的产率得到(E)-4-(3-nitrophenyl)but-3-en-1-ol
  参考文献：
  名称：

  烯丙基醇对手性β-氯四氢呋喃的合成的不对称5-内基氯醚化。

  摘要：

  成功开发了均丙醇的不对称5内基氯醚化反应，该方法采用了一种容易获得的，从辛可宁衍生而来的季铵盐作为常规有机催化剂。这种方法可以很容易地获得对映选择性高的β-氯四氢呋喃。

  DOI：

  10.1039/c2cc38436a

文献信息

• 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
  申请人：Pfizer Inc.

  公开号：US20020072616A1

  公开（公告）日：2002-06-13

  Compounds of formula (I), their salts and prodrugs thereof, where the substituents are as defined herein are disclosed as opiate binding agents useful in the treatment of opiate-mediated conditions. Also described are processes for making such substances. 1

  公开了式（I）的化合物、其盐和前药，其中取代基如此定义，作为治疗鸦片类介导疾病的鸦片受体结合剂。还描述了制造这种物质的过程。
• IDO INHIBITORS
  申请人：Newlink Genetics

  公开号：EP2227233A2

  公开（公告）日：2010-09-15
• [EN] IDO INHIBITORS<br/>[FR] INHIBITEURS DE L'IDO
  申请人：NEWLINK GENETICS

  公开号：WO2009073620A2

  公开（公告）日：2009-06-11

  Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunosuppression associated with an infectious disease, e.g., HIV-I infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein.